Clinical Trial Update: A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty [Phase 2]

View source ↗

Summary

A Phase 2 feasibility dose-escalating trial of MDT-10013 for acute postoperative pain after total knee arthroplasty has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• MDT-10013

Snippet

Sponsor: Medtronic Spinal and Biologics | Conditions: Post-operation Pain | Phase 2 | Status: WITHDRAWN